Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR NASDAQ:URGN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$72.92+1.4%$68.16$21.02▼$109.00$2.46B1.131.12 million shs692,225 shsURGNUrogen Pharma$40.23+5.8%$30.66$13.55▼$40.34$1.96B1.56789,561 shs617,932 shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics-4.01%+11.66%+26.99%-7.64%+216.32%URGNUrogen Pharma+0.74%+0.24%+39.56%+85.24%+177.39%VERVVerve Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$72.92+1.4%$68.16$21.02▼$109.00$2.46B1.131.12 million shs692,225 shsURGNUrogen Pharma$40.23+5.8%$30.66$13.55▼$40.34$1.96B1.56789,561 shs617,932 shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics-4.01%+11.66%+26.99%-7.64%+216.32%URGNUrogen Pharma+0.74%+0.24%+39.56%+85.24%+177.39%VERVVerve Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.73Moderate Buy$149.63105.19% UpsideURGNUrogen Pharma 2.88Moderate Buy$39.50-1.81% DownsideVERVVerve Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest URGN, NKTR, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026URGNUrogen Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/2/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/18/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/11/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/11/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$95.00 ➝ $80.005/11/2026URGNUrogen Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.005/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.005/7/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $40.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$55.23M44.61N/AN/A$4.41 per share16.54URGNUrogen Pharma$109.79M17.85N/AN/A($2.25) per share-17.88VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A28.74N/A-94.83%N/A-62.85%8/6/2026 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest URGN, NKTR, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NKTRNektar Therapeutics-$2.05N/AN/AN/A$10.38 millionN/A8/6/2026Q2 2026URGNUrogen Pharma-$0.2942N/AN/AN/A$62.16 millionN/A5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A10.2110.21URGNUrogen PharmaN/A4.694.28VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%URGNUrogen Pharma91.29%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics2.50%URGNUrogen Pharma4.80%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableURGN, NKTR, and VERV HeadlinesRecent News About These CompaniesGoodbye daily statins? VERVE-102 aims to cut LDL cholesterol in one shotJune 8, 2026 | msn.comBig pharma all-in on gene therapy after obesity successMay 31, 2026 | msn.comPCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterolMay 29, 2026 | healio.comHA one-time experimental treatment might control cholesterol for lifeMay 29, 2026 | msn.comPharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and moreMay 28, 2026 | statnews.comSA gene therapy lowered cholesterol in early trial results. It has a Philly backstory.May 28, 2026 | inquirer.comICan one treatment lower cholesterol and reduce heart attack risk for years?May 26, 2026 | business-standard.comBCan an injection prevent heart attacks? Eli Lilly’s gene-editing therapy cuts LDL cholesterol by 62%May 26, 2026 | indianexpress.comILilly says gene editing therapy cut “bad” cholesterol in early-stage trialMay 26, 2026 | seekingalpha.comSo Far, So Good for PCSK9-Targeting Gene Therapy in HypercholesterolemiaMay 26, 2026 | medpagetoday.comMLilly is looking for its next act beyond the weight-loss boomMay 26, 2026 | msn.comEli Lilly-backed gene-editing therapy cuts ‘bad’ cholesterol by up to 62% in early trialMay 26, 2026 | cnbctv18.comCLilly says gene editing therapy cut bad cholesterol in early-stage trialMay 26, 2026 | msn.comLilly advances gene therapy, snaps up vaccine makers. It’s looking beyond weight lossMay 26, 2026 | msn.comLilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitorsMay 25, 2026 | fiercebiotech.comFIn Vivo Base Editing of PCSK9 with VERVE-102 for HypercholesterolemiaMay 25, 2026 | nejm.orgNEli Lilly says Verve’s gene editor lowers cholesterol levels in early studyMay 25, 2026 | statnews.comSThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comEuropean Biotechs Developing Next-Generation of Cardiometabolic and Precision Cardiology TherapeuticsApril 14, 2026 | pharmtech.comPStudies test whether gene-editing can fix high cholesterolFebruary 17, 2026 | tribtoday.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, NKTR, and VERV Company DescriptionsNektar Therapeutics NASDAQ:NKTR$72.92 +1.02 (+1.42%) Closing price 04:00 PM EasternExtended Trading$71.90 -1.02 (-1.40%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Urogen Pharma NASDAQ:URGN$40.23 +2.20 (+5.78%) Closing price 04:00 PM EasternExtended Trading$39.86 -0.36 (-0.91%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
